| Description | Human RRAGD (Rag D) knockout Hela TG cell line is edited by our special CRISPR/Cas9 technology. HeLa TG cell line is from the human uterine cervix. |
| Size | 1 vial (2*106 cells/vial) |
| Parental Cell Line | HeLa TG |
| Biosafety Level | 2 |
| Format | Frozen |
| Culture Conditions | Cultured at 37°C with 5% CO2. |
| Culture Medium | Eagle's minimal essential medium wityh 10% fetal calf serum |
| Subculture Conditions | Cells are treated with 0.25% trypsin |
| Subculture Guidelines | All seeding densities should be based on cell counts obtained by established methods. The recommended seeding density is 2*104 cells/cm2. |
| Knockout Validation | Sanger Sequencing, Western Blot (WB) |
| Viability | >95% viability before freezing. |
| Adherent /Suspension | Adherent |
| Disease | Human papillomavirus-related endocervical adenocarcinoma |
| Purity | Immunogen affinity purified |
| Storage | Vapor phase of liquid nitrogen |
| Sterility | All cells test negative for bacteria, yeast, and fungi. |
| Shipping Info | Dry Ice |
| Species | Human |
| Tested Applications | Suitable for: ICC, WB |
| Tissue | Uterine cervix |
| Recommended Control | Human wild-type Hela TG cell line |
| Morphology | Epithelial |
| Pathogens | HIV: Negative Hepatitis B: Negative Hepatitis C: Negative |
| Applications | For research use only |
| Product Type | Knockout Stable Cell Line |
| Price | Inquiry |
